Copyright
©2012 Baishideng Publishing Group Co.
World J Cardiol. Mar 26, 2012; 4(3): 66-71
Published online Mar 26, 2012. doi: 10.4330/wjc.v4.i3.66
Published online Mar 26, 2012. doi: 10.4330/wjc.v4.i3.66
Table 3 Pharmacological treatments of patients with heart failure, comparing those with and without chronic obstructive pulmonary disease for June 2007 to June 2010 n (%)
Treatment | HF patients with COPD (n = 101) | HF patients without COPD (n = 682) |
Cardiovascular treatment | ||
Beta-blocker | 21 (22)b | 555 (81) |
ACE-inhibitor | 49 (49) | 382 (56) |
Angiotensin receptor blocker | 11 (11) | 82 (12) |
Spironolactone | 54 (54)b | 189 (28) |
Loop diuretic | 61 (61)b | 525 (77) |
Calcium channel blocker | 31 (31) | 184 (27) |
Amiodarone | 5 (5) | 41 (6) |
Aspirin | 60 (60) | 436 (64) |
Warfarin | 15 (15)b | 130 (20) |
COPD treatment | ||
Beta agonist | 61 (61)b | 20 (3) |
Inhaled anti-muscarinic | 27 (27)b | 6 (1) |
Inhaled steroid | 53 (53)b | 19 (3) |
Oral steroids | 24 (24)b | 2 (0.003) |
- Citation: O’Kelly N, Robertson W, Smith J, Dexter J, Carroll-Hawkins C, Ghosh S. Short-term outcomes in heart failure patients with chronic obstructive pulmonary disease in the community. World J Cardiol 2012; 4(3): 66-71
- URL: https://www.wjgnet.com/1949-8462/full/v4/i3/66.htm
- DOI: https://dx.doi.org/10.4330/wjc.v4.i3.66